Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The NCCN Guidelines specific to management of large clinical stage II and III tumors are discussed in this article. These guidelines are the work of the members of the NCCN Breast Cancer Panel. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. Although not stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer.

  • 1.

    SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:929.

  • 2.

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:16871717.

    • Search Google Scholar
    • Export Citation
  • 3.

    SiegelRWardEBrawleyOJemalA. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin2011;61:212236.

    • Search Google Scholar
    • Export Citation
  • 4.

    BerryDACroninKAPlevritisSK. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med2005;353:17841792.

    • Search Google Scholar
    • Export Citation
  • 5.

    WhiteJMorrowMMoughanJ. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer2003;97:893904.

    • Search Google Scholar
    • Export Citation
  • 6.

    WilkinsonNWShahryarinejadAWinstonJS. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg2003;196:38–-43.

    • Search Google Scholar
    • Export Citation
  • 7.

    AllredDCHarveyJMBerardoMClarkGM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol1998;11:155168.

    • Search Google Scholar
    • Export Citation
  • 8.

    RhodesAJasaniBBarnesDM. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol2000;53:125130.

    • Search Google Scholar
    • Export Citation
  • 9.

    RudigerTHoflerHKreipeHH. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol2002;26:873882.

    • Search Google Scholar
    • Export Citation
  • 10.

    AllredDCCarlsonRWBerryDA. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw2009;7(Suppl 6):S121; quiz S22-23.

    • Search Google Scholar
    • Export Citation
  • 11.

    HammondMEHHayesDFDowsettM. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol2010;28:27842795.

    • Search Google Scholar
    • Export Citation
  • 12.

    HammondME. ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol2011;19:499500.

  • 13.

    WangSSaboorianMHFrenkelE. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol2000;53:374381.

    • Search Google Scholar
    • Export Citation
  • 14.

    DybdalNLeibermanGAndersonS. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat2005;93:311.

    • Search Google Scholar
    • Export Citation
  • 15.

    PaikSBryantJTan-ChiuE. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst2002;94:852854.

    • Search Google Scholar
    • Export Citation
  • 16.

    PaikSTan-ChiuEBryantJ. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin [abstract]. Breast Cancer Res Treat2002;76(Suppl):Abstract S31.

    • Search Google Scholar
    • Export Citation
  • 17.

    PerezEASumanVJDavidsonNE. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol2006;24:30323038.

    • Search Google Scholar
    • Export Citation
  • 18.

    TubbsRRPettayJDRochePC. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol2001;19:27142721.

    • Search Google Scholar
    • Export Citation
  • 19.

    PressMFSauterGBernsteinL. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res2005;11:65986607.

    • Search Google Scholar
    • Export Citation
  • 20.

    WolffACHammondMEHicksDG. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol2013;31:39974013.

    • Search Google Scholar
    • Export Citation
  • 21.

    WolffACHammondMEHicksDG. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline update. Arch Pathol Lab Med2014;138:241256.

    • Search Google Scholar
    • Export Citation
  • 22.

    GiordanoSHBuzdarAUHortobagyiGN. Breast cancer in men. Ann Intern Med2002;137:678687.

  • 23.

    GiordanoSHValeroVBuzdarAUHortobagyiGN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol2002;25:235237.

  • 24.

    EssermanL. Integration of imaging in the management of breast cancer. J Clin Oncol2005;23:16011602.

  • 25.

    GundryKR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park)2005;19:159169.

  • 26.

    HoussamiNCiattoSMacaskillP. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol2008;26:32483258.

    • Search Google Scholar
    • Export Citation
  • 27.

    LehmanCDDeMartiniWAndersonBOEdgeSB. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw2009;7:193201.

    • Search Google Scholar
    • Export Citation
  • 28.

    FischerUZachariaeOBaumF. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol2004;14:17251731.

    • Search Google Scholar
    • Export Citation
  • 29.

    SolinLJOrelSGHwangWT. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol2008;26:386391.

    • Search Google Scholar
    • Export Citation
  • 30.

    Members of the Breast Cancer Disease Site Group. Baseline staging tests in primary breast cancer. HammCTeyR reviewers. Toronto (ON): Cancer Care Ontario; 2011Nov1[Endorsed 2011 Oct 11]. Program in Evidence-based Care Evidence-Based Series No.: 1-14 Version 2.

    • Search Google Scholar
    • Export Citation
  • 31.

    PuglisiFFolladorAMinisiniAM. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol2005;16:263266.

    • Search Google Scholar
    • Export Citation
  • 32.

    AukemaTSStraverMEPeetersMJ. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer2010;46:32053210.

    • Search Google Scholar
    • Export Citation
  • 33.

    FusterDDuchJParedesP. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol2008;26:47464751.

    • Search Google Scholar
    • Export Citation
  • 34.

    GroheuxDMorettiJLBailletG. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys2008;71:695704.

    • Search Google Scholar
    • Export Citation
  • 35.

    PodoloffDAAdvaniRHAllredC. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw2007;5(Suppl 1):S122; quiz 23-24.

    • Search Google Scholar
    • Export Citation
  • 36.

    RosenELEubankWBMankoffDA. FDG PET, PET/CT, and breast cancer imaging. Radiographics2007;27(Suppl 1):S215229.

  • 37.

    van der HoevenJJMKrakNCHoekstraOS. 18F(2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol2004;22:12531259.

    • Search Google Scholar
    • Export Citation
  • 38.

    NiikuraNCostelloeCMMadewellJE. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist2011;16:11111119.

    • Search Google Scholar
    • Export Citation
  • 39.

    MorrisPGLynchCFeeneyJN. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol2010;28:31543159.

    • Search Google Scholar
    • Export Citation
  • 40.

    AlessioAMKinahanPEChengPM. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am2004;42:10171032.

  • 41.

    WongTZPaulsonEKNelsonRC. Practical approach to diagnostic CT combined with PET. AJR Am J Roentgenol2007;188:622629.

  • 42.

    KranickJASchaeferCRowellS. Is pregnancy after breast cancer safe?Breast J2010;16:404411.

  • 43.

    CruzMRPrestesJCGimenesDLFanelliMF. Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review. Fertil Steril2010;94:138143.

    • Search Google Scholar
    • Export Citation
  • 44.

    DunnLFoxKR. Techniques for fertility preservation in patients with breast cancer. Curr Opin Obstet Gynecol2009;21:6873.

  • 45.

    OktemOOktayK. Fertility preservation for breast cancer patients. Semin Reprod Med2009;27:486492.

  • 46.

    RedigAJBranniganRStrykerSJ. Incorporating fertility preservation into the care of young oncology patients. Cancer2011;117:410.

  • 47.

    LeeSOzkavukcuSHeytensE. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol2010;28:46834686.

    • Search Google Scholar
    • Export Citation
  • 48.

    LoboRA. Potential options for preservation of fertility in women. N Engl J Med2005;353:6473.

  • 49.

    SukumvanichPCaseLDVan ZeeK. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer2010;116:31023111.

    • Search Google Scholar
    • Export Citation
  • 50.

    PeateMMeiserBFriedlanderM. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer—an Australian fertility decision aid collaborative group study. J Clin Oncol2011;29:16701677.

    • Search Google Scholar
    • Export Citation
  • 51.

    AlkuwariEAugerM. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. Cancer2008;114:8993.

    • Search Google Scholar
    • Export Citation
  • 52.

    ClasseJMBordesVCampionL. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol2009;27:726732.

    • Search Google Scholar
    • Export Citation
  • 53.

    HuntKKYiMMittendorfEA. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg2009;250:558566.

    • Search Google Scholar
    • Export Citation
  • 54.

    KuehnTVoglFDHelmsG. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol2004;30:252259.

    • Search Google Scholar
    • Export Citation
  • 55.

    KuehnTBauerfeindIFehmT. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol2013;14:609618.

    • Search Google Scholar
    • Export Citation
  • 56.

    BougheyJCSumanVJMittendorfEA. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA2013;310:14551461.

    • Search Google Scholar
    • Export Citation
  • 57.

    FisherBBryantJWolmarkN. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol1998;16:26722685.

    • Search Google Scholar
    • Export Citation
  • 58.

    BearHDAndersonSSmithRE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol2006;24:20192027.

    • Search Google Scholar
    • Export Citation
  • 59.

    HortobagyiGNSingletarySEStromEA. Treatment of locally advanced and inflammatory breast cancer. In: HarrisJRLippmanMEMorrowMOsborneCK eds. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2004:645660.

    • Search Google Scholar
    • Export Citation
  • 60.

    HudisCModiS. Preoperative chemotherapy for breast cancer: miracle or mirage?JAMA2007;298:26652667.

  • 61.

    BuzdarAUIbrahimNKFrancisD. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol2005;23:36763685.

    • Search Google Scholar
    • Export Citation
  • 62.

    BuzdarAUValeroVIbrahimNK. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res2007;13:228233.

    • Search Google Scholar
    • Export Citation
  • 63.

    UntchMLoiblSBischoffJ. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol2012;13:135144.

    • Search Google Scholar
    • Export Citation
  • 64.

    BaselgaJBradburyIEidtmannH. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet2012;379:633640.

    • Search Google Scholar
    • Export Citation
  • 65.

    Piccart-GebhartMHolmesAde AzambujaE. The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06). [abstract]. Presented at the 2013 San Antonio Breast Cancer Symposium; December10-142013; San Antonio, Texas. Abstract S1-01.

    • Search Google Scholar
    • Export Citation
  • 66.

    ScheuerWFriessTBurtscherH. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res2009;69:93309336.

    • Search Google Scholar
    • Export Citation
  • 67.

    BaselgaJCortesJImSA. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) [abstract]. Cancer Res2012;72(24 Suppl):Abstract S5-1.

    • Search Google Scholar
    • Export Citation
  • 68.

    SwainSKimS-BCortesJ. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) [abstract]. Cancer Res2012;72(24 Suppl):Abstract P5-18-26.

    • Search Google Scholar
    • Export Citation
  • 69.

    SchneeweissAChiaSHickishT. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol2013;24:22782284.

    • Search Google Scholar
    • Export Citation
  • 70.

    GianniLPienkowskiTImYH. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol2012;13:2532.

    • Search Google Scholar
    • Export Citation
  • 71.

    EllisMJCoopASinghB. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol2001;19:38083816.

    • Search Google Scholar
    • Export Citation
  • 72.

    SmithIEDowsettMEbbsSR. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol2005;23:51085116.

    • Search Google Scholar
    • Export Citation
  • 73.

    BassSSLymanGHMcCannCR. Lymphatic mapping and sentinel lymph node biopsy. Breast J1999;5:288295.

  • 74.

    CoxCE. Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol2001;8:67S70S.

  • 75.

    CoxCENguyenKGrayRJ. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS?Am Surg2001;67:513519.

  • 76.

    KragDWeaverDAshikagaT. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med1998;339:941946.

  • 77.

    KragDNAndersonSJJulianTB. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients [abstract]. J Clin Oncol2010;28(Suppl 18):Abstract LBA505.

    • Search Google Scholar
    • Export Citation
  • 78.

    LymanGHGiulianoAESomerfieldMR. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol2005;23:77037720.

    • Search Google Scholar
    • Export Citation
  • 79.

    McMastersKMGiulianoAERossMI. Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care. N Engl J Med1998;339:990995.

    • Search Google Scholar
    • Export Citation
  • 80.

    O’HeaBJHillADEl-ShirbinyAM. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg1998;186:423427.

    • Search Google Scholar
    • Export Citation
  • 81.

    VeronesiUPaganelliGVialeG. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med2003;349:546553.

    • Search Google Scholar
    • Export Citation
  • 82.

    ManselREFallowfieldLKissinM. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst2006;98:599609.

    • Search Google Scholar
    • Export Citation
  • 83.

    CoxCESaludCJCantorA. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg2001;193:593600.

    • Search Google Scholar
    • Export Citation
  • 84.

    DupontECoxCShiversS. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res2001;97:9296.

  • 85.

    GiulianoAEHawesDBallmanKV. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA2011;306:385393.

    • Search Google Scholar
    • Export Citation
  • 86.

    DegnimACReynoldsCPantvaidyaG. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg2005;190:543550.

    • Search Google Scholar
    • Export Citation
  • 87.

    HouvenaeghelGNosCGiardS. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol2009;35:690695.

    • Search Google Scholar
    • Export Citation
  • 88.

    KatzASmithBLGolshanM. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol2008;26:20932098.

    • Search Google Scholar
    • Export Citation
  • 89.

    KohrtHEOlshenRABermasHR. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer2008;8:66.

    • Search Google Scholar
    • Export Citation
  • 90.

    ScowJSDegnimACHoskinTL. Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer2009;115:40644070.

    • Search Google Scholar
    • Export Citation
  • 91.

    van la ParraRFErnstMFBevilacquaJL. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol2009;16:11281135.

    • Search Google Scholar
    • Export Citation
  • 92.

    WerkoffGLambaudieEFondrinierE. Prospective multicenter comparison of models to predict four or more involved axillary lymph nodes in patients with breast cancer with one to three metastatic sentinel lymph nodes. J Clin Oncol2009;27:57075712.

    • Search Google Scholar
    • Export Citation
  • 93.

    GiulianoAEMcCallLBeitschP. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg2010;252:426432; discussion 432-423.

    • Search Google Scholar
    • Export Citation
  • 94.

    GiulianoAEHuntKKBallmanKV. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA2011;305:569575.

    • Search Google Scholar
    • Export Citation
  • 95.

    AxelssonCKMouridsenHTZedelerK. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer1992;28A:14151418.

    • Search Google Scholar
    • Export Citation
  • 96.

    KiricutaCITauschJ. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer1992;69:24962501.

    • Search Google Scholar
    • Export Citation
  • 97.

    FisherBRedmondCFisherER. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med1985;312:674681.

    • Search Google Scholar
    • Export Citation
  • 98.

    HellmanS. Stopping metastases at their source. N Engl J Med1997;337:996997.

  • 99.

    OvergaardMHansenPSOvergaardJ. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med1997;337:949955.

    • Search Google Scholar
    • Export Citation
  • 100.

    OvergaardMJensenMBOvergaardJ. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet1999;353:16411648.

    • Search Google Scholar
    • Export Citation
  • 101.

    RagazJOlivottoIASpinelliJJ. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst2005;97:116126.

    • Search Google Scholar
    • Export Citation
  • 102.

    RechtAEdgeSBSolinLJ. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol2001;19:15391569.

    • Search Google Scholar
    • Export Citation
  • 103.

    HuangEHTuckerSLStromEA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol2004;22:46914699.

    • Search Google Scholar
    • Export Citation
  • 104.

    McGuireSEGonzalez-AnguloAMHuangEH. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys2007;68:10041009.

    • Search Google Scholar
    • Export Citation
  • 105.

    ClarkeMCollinsRDarbyS. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;366:20872106.

    • Search Google Scholar
    • Export Citation
  • 106.

    OvergaardMNielsenHMOvergaardJ. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol2007;82:247253.

    • Search Google Scholar
    • Export Citation
  • 107.

    WhelanTJOlivottoIAckermanI. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer [abstract]. J Clin Oncol2011;29 (18 Suppl):Abstract LBA1003.

    • Search Google Scholar
    • Export Citation
  • 108.

    WhelanTJPignolJPLevineMN. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med2010;362:513520.

  • 109.

    GroupSTBentzenSMAgrawalRK. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet2008;371:10981107.

    • Search Google Scholar
    • Export Citation
  • 110.

    GroupSTBentzenSMAgrawalRK. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol2008;9:331341.

    • Search Google Scholar
    • Export Citation
  • 111.

    NielsenHMOvergaardMGrauC. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol2006;24:22682275.

    • Search Google Scholar
    • Export Citation
  • 112.

    AhmedSSnellingABainsMWhitworthIH. Breast reconstruction. BMJ2005;330:943948.

  • 113.

    EdlichRFWintersKLFaulknerBC. Advances in breast reconstruction after mastectomy. J Long Term Eff Med Implants2005;15:197207.

  • 114.

    PenningtonDG. Breast reconstruction after mastectomy: current state of the art. ANZ J Surg2005;75:454458.

  • 115.

    ChangDW. Breast Reconstruction with Microvascular MS-TRAM and DIEP Flaps. Arch Plast Surg2012;39:310.

  • 116.

    Garcia-EtienneCACody IiiHS3rdDisaJJ. Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J2009;15:440449.

    • Search Google Scholar
    • Export Citation
  • 117.

    PetitJYVeronesiUOrecchiaR. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat2009;117:333338.

    • Search Google Scholar
    • Export Citation
  • 118.

    YuehJHHoulihanMJSlavinSA. Nipple-sparing mastectomy: evaluation of patient satisfaction, aesthetic results, and sensation. Ann Plast Surg2009;62:586590.

    • Search Google Scholar
    • Export Citation
  • 119.

    ChungAPSacchiniV. Nipple-sparing mastectomy: where are we now?Surg Oncol2008;17:261266.

  • 120.

    GerberBKrauseADieterichM. The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study. Ann Surg2009;249:461468.

    • Search Google Scholar
    • Export Citation
  • 121.

    MallonPFeronJGCouturaudB. The role of nipple-sparing mastectomy in breast cancer: a comprehensive review of the literature. Plast Reconstr Surg2013;131:969984.

    • Search Google Scholar
    • Export Citation
  • 122.

    PiperMPeledAWFosterRD. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surgin press.

    • Search Google Scholar
    • Export Citation
  • 123.

    TothBAForleyBGCalabriaR. Retrospective study of the skin-sparing mastectomy in breast reconstruction. Plast Reconstr Surg1999;104:7784.

    • Search Google Scholar
    • Export Citation
  • 124.

    CarlsonGWStybloTMLylesRH. The use of skin sparing mastectomy in the treatment of breast cancer: the Emory experience. Surg Oncol2003;12:265269.

    • Search Google Scholar
    • Export Citation
  • 125.

    DownesKJGlattBSKanchwalaSK. Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer2005;103:906913.

    • Search Google Scholar
    • Export Citation
  • 126.

    FosterRDEssermanLJAnthonyJP. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol2002;9:462466.

    • Search Google Scholar
    • Export Citation
  • 127.

    Medina-FrancoHVasconezLOFixRJ. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg2002;235:814819.

    • Search Google Scholar
    • Export Citation
  • 128.

    NewmanLAKuererHMHuntKK. Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol1998;5:620626.

    • Search Google Scholar
    • Export Citation
  • 129.

    KronowitzSJRobbGL. Radiation therapy and breast reconstruction: a critical review of the literature. Plast Reconstr Surg2009;124:395408.

    • Search Google Scholar
    • Export Citation
  • 130.

    TranNVChangDWGuptaA. Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg2001;108:7882.

    • Search Google Scholar
    • Export Citation
  • 131.

    MehtaVKGoffinetD. Postmastectomy radiation therapy after TRAM flap breast reconstruction. Breast J2004;10:118122.

  • 132.

    CloughKBKaufmanGJNosC. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol2010;17:13751391.

    • Search Google Scholar
    • Export Citation
  • 133.

    AndersonBOMasettiRSilversteinMJ. Oncoplastic approaches to partial mastectomy: an overview of volume-displacement techniques. Lancet Oncol2005;6:145157.

    • Search Google Scholar
    • Export Citation
  • 134.

    HuemerGMSchrenkPMoserF. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg2007;120:390398.

    • Search Google Scholar
    • Export Citation
  • 135.

    KaurNPetitJYRietjensM. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol2005;12:539545.

    • Search Google Scholar
    • Export Citation
  • 136.

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)PetoRDaviesC. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet2012;379:432444.

    • Search Google Scholar
    • Export Citation
  • 137.

    LoprinziCLThomeSD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol2001;19:972979.

  • 138.

    RavdinPMSiminoffLADavisGJ. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol2001;19:980991.

    • Search Google Scholar
    • Export Citation
  • 139.

    MussHBBerryDACirrincioneCT. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med2009;360:20552065.

  • 140.

    OlivottoIABajdikCDRavdinPM. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol2005;23:27162725.

    • Search Google Scholar
    • Export Citation
  • 141.

    LoprinziCLRavdinPM. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw2003;1:189196.

    • Search Google Scholar
    • Export Citation
  • 142.

    CookeTReevesJLaniganAStantonP. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol2001;12(Suppl 1):2328.

  • 143.

    PaikSBryantJParkC. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst1998;90:13611370.

    • Search Google Scholar
    • Export Citation
  • 144.

    PaikSBryantJTan-ChiuE. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst2000;92:19911998.

    • Search Google Scholar
    • Export Citation
  • 145.

    PiccartMJDi LeoAHamiltonA. HER2. a ‘predictive factor’ ready to use in the daily management of breast cancer patients?Eur J Cancer2000;36:17551761.

    • Search Google Scholar
    • Export Citation
  • 146.

    PritchardKIShepherdLEO’MalleyFP. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med2006;354:21032111.

    • Search Google Scholar
    • Export Citation
  • 147.

    ThorADBerryDABudmanDR. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst1998;90:13461360.

    • Search Google Scholar
    • Export Citation
  • 148.

    DresslerLGBerryDABroadwaterG. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol2005;23:42874297.

    • Search Google Scholar
    • Export Citation
  • 149.

    JoensuuHKellokumpu-LehtinenPlBonoP. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med2006;354:809820.

    • Search Google Scholar
    • Export Citation
  • 150.

    Piccart-GebhartMJProcterMLeyland-JonesB. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med2005;353:16591672.

    • Search Google Scholar
    • Export Citation
  • 151.

    GoldhirschAPiccart-GebhartMProcterM. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res2012;72:S52.

    • Search Google Scholar
    • Export Citation
  • 152.

    RomondEPerezEBryantJ. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med2005;353:16731684.

    • Search Google Scholar
    • Export Citation
  • 153.

    RomondESumanVJeongJH. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Cancer Res2012;72(24 Suppl):S5.

    • Search Google Scholar
    • Export Citation
  • 154.

    SlamonDEiermannWRobertN. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med2011;365:12731283.

  • 155.

    CobleighMAVogelCLTripathyD. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol1999;17:26392648.

    • Search Google Scholar
    • Export Citation
  • 156.

    SlamonDJLeyland-JonesBShakS. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001;344:783792.

    • Search Google Scholar
    • Export Citation
  • 157.

    VogelCLCobleighMATripathyD. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol2002;20:719726.

    • Search Google Scholar
    • Export Citation
  • 158.

    JeffreySSLonningPEHillnerBE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw2005;3:291300.

    • Search Google Scholar
    • Export Citation
  • 159.

    PerouCMJeffreySSvan de RijnM. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A1999;96:92129217.

    • Search Google Scholar
    • Export Citation
  • 160.

    SorlieTPerouCMTibshiraniR. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A2001;98:1086910874.

    • Search Google Scholar
    • Export Citation
  • 161.

    SorlieTTibshiraniRParkerJ. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A2003;100:84188423.

    • Search Google Scholar
    • Export Citation
  • 162.

    PaikSShakSTangG. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med2004;351:28172826.

    • Search Google Scholar
    • Export Citation
  • 163.

    PaikSTangGShakS. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol2006;24:37263734.

    • Search Google Scholar
    • Export Citation
  • 164.

    FanCOhDSWesselsL. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med2006;355:560569.

  • 165.

    WangYKlijnJGZhangY. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet2005;365:671679.

    • Search Google Scholar
    • Export Citation
  • 166.

    GlasAMFlooreADelahayeLJ. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics2006;7:278.

    • Search Google Scholar
    • Export Citation
  • 167.

    van de VijverMJHeYDvan’t VeerLJ. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med2002;347:19992009.

    • Search Google Scholar
    • Export Citation
  • 168.

    van ‘t VeerLJDaiHvan de VijverMJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature2002;415:530536.

  • 169.

    KnauerMMookSRutgersEJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat2010;120:655661.

    • Search Google Scholar
    • Export Citation
  • 170.

    KunzG. Use of a genomic test (MammaPrint) in daily clinical practice to assist in risk stratification of young breast cancer patients. Arch Gynecol Obstet2011;283:597602.

    • Search Google Scholar
    • Export Citation
  • 171.

    IshitobiMGoranovaTEKomoikeY. Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol2010;40:508512.

    • Search Google Scholar
    • Export Citation
  • 172.

    MookSKnauerMBueno-de-MesquitaJM. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol2010;17:14061413.

    • Search Google Scholar
    • Export Citation
  • 173.

    A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/-chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurence score (RS) of 25 or less. RXPONDER: a clinical trial RX for positive node endocrine responsive breast cancer. ClinicalTrials.govidentifier: NCT01272037.

    • Search Google Scholar
    • Export Citation
  • 174.

    MINDACT (Microarray In Node-Negative and 1 to 3 positive lymph node disease may avoid chemotherapy): a prospective randomized study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. ClinicalTrials.govidentifier: NCT00433589.

    • Search Google Scholar
    • Export Citation
  • 175.

    AlbainKSBarlowWEShakS. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol2010;11:5565.

    • Search Google Scholar
    • Export Citation
  • 176.

    Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (The TAILORx Trial). ClinicalTrials.govidentifier: NCT00310180.

    • Search Google Scholar
    • Export Citation
  • 177.

    SwainSMWilsonJWMamounasEP. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst2004;96:516523.

    • Search Google Scholar
    • Export Citation
  • 178.

    BerryDACirrincioneCHendersonIC. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA2006;295:16581667.

    • Search Google Scholar
    • Export Citation
  • 179.

    AlbainKSBarlowWERavdinPM. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374:20552063.

    • Search Google Scholar
    • Export Citation
  • 180.

    Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet1998;351:14511467.

    • Search Google Scholar
    • Export Citation
  • 181.

    ArpinoGGreenSJAllredDC. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res2004;10:56705676.

    • Search Google Scholar
    • Export Citation
  • 182.

    BerryDAMussHBThorAD. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol2000;18:34713479.

    • Search Google Scholar
    • Export Citation
  • 183.

    De LaurentiisMArpinoGMassarelliE. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res2005;11:47414748.

    • Search Google Scholar
    • Export Citation
  • 184.

    Eppenberger-CastoriSKuengWBenzC. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol2001;19:645656.

    • Search Google Scholar
    • Export Citation
  • 185.

    KnoopASBentzenSMNielsenMM. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol2001;19:33763384.

    • Search Google Scholar
    • Export Citation
  • 186.

    MassR. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol2000;27:4652.

  • 187.

    PaikSShakSTangG. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol2005;23(Suppl 16):Abstract 510.

    • Search Google Scholar
    • Export Citation
  • 188.

    PegramMDPaulettiGSlamonDJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat1998;52:6577.

    • Search Google Scholar
    • Export Citation
  • 189.

    DowsettMAllredCKnoxJ. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol2008;26:10591065.

    • Search Google Scholar
    • Export Citation
  • 190.

    Early Breast Cancer Trialists’ Collaborative GDaviesCGodwinJ. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet2011;378:771784.

    • Search Google Scholar
    • Export Citation
  • 191.

    Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:16871717.

    • Search Google Scholar
    • Export Citation
  • 192.

    DaviesCPanHGodwinJ. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet2013;381:805816.

    • Search Google Scholar
    • Export Citation
  • 193.

    GrayRReaDHandleyK. aTTom (adjuvant Tamoxifen— To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results [abstract]. J Clin Oncol2008;(15 Suppl):Abstract 513.

    • Search Google Scholar
    • Export Citation
  • 194.

    PritchardKI. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations. Oncology (Williston Park)2009;23:2733.

    • Search Google Scholar
    • Export Citation
  • 195.

    PuhallaSBrufskyADavidsonN. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast2009;18(Suppl 3):S122130.

  • 196.

    TanSHWolffAC. The role of ovarian ablation in the adjuvant therapy of breast cancer. Curr Oncol Rep2008;10:2737.

  • 197.

    CuzickJAmbroisineLDavidsonN. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet2007;369:17111723.

    • Search Google Scholar
    • Export Citation
  • 198.

    DavidsonNEO’NeillAMVukovAM. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol2005;23:59735982.

    • Search Google Scholar
    • Export Citation
  • 199.

    EjlertsenBMouridsenHTJensenMB. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol2006;24:49564962.

    • Search Google Scholar
    • Export Citation
  • 200.

    GoelSSharmaRHamiltonABeithJ. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev2009:CD004562.

    • Search Google Scholar
    • Export Citation
  • 201.

    KaufmannMJonatWBlameyR. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer2003;39:17111717.

    • Search Google Scholar
    • Export Citation
  • 202.

    SchmidPUntchMWallwienerD. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res2002;22:23252332.

    • Search Google Scholar
    • Export Citation
  • 203.

    ThomsonCSTwelvesCJMallonEALeakeRE. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast2002;11:419429.

    • Search Google Scholar
    • Export Citation
  • 204.

    von MinckwitzGGrafEGeberthM. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer2006;42:17801788.

    • Search Google Scholar
    • Export Citation
  • 205.

    Castiglione-GertschMO’NeillAPriceKN. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst2003;95:18331846.

    • Search Google Scholar
    • Export Citation
  • 206.

    RocheHFumoleauPSpielmannM. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol2006;24:56645671.

    • Search Google Scholar
    • Export Citation
  • 207.

    BoccardoFRubagottiAAmorosoD. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol2000;18:27182727.

    • Search Google Scholar
    • Export Citation
  • 208.

    CoombesRCKilburnLSSnowdonCF. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet2007;369:559570.

    • Search Google Scholar
    • Export Citation
  • 209.

    KaufmannMJonatWHilfrichJ. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol2007;25:26642670.

    • Search Google Scholar
    • Export Citation
  • 210.

    GossPEIngleJNMartinoS. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst2005;97:12621271.

    • Search Google Scholar
    • Export Citation
  • 211.

    ForbesJFCuzickJBuzdarA. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol2008;9:4553.

    • Search Google Scholar
    • Export Citation
  • 212.

    ThurlimannBKeshaviahACoatesAS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med2005;353:27472757.

    • Search Google Scholar
    • Export Citation
  • 213.

    BaumMBudzarAUCuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet2002;359:21312139.

    • Search Google Scholar
    • Export Citation
  • 214.

    HowellACuzickJBaumM. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet2005;365:6062.

    • Search Google Scholar
    • Export Citation
  • 215.

    DuffySJacksonTLLansdownM. The ATAC (’Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod2006;21:545553.

    • Search Google Scholar
    • Export Citation
  • 216.

    FallowfieldLCellaDCuzickJ. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer trial. J Clin Oncol2004;22:42614271.

    • Search Google Scholar
    • Export Citation
  • 217.

    EastellRAdamsJEColemanRE. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol2008;26:10511057.

    • Search Google Scholar
    • Export Citation
  • 218.

    DowsettMCuzickJHowellAJacksonI. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer2001;85:317324.

    • Search Google Scholar
    • Export Citation
  • 219.

    BuzdarAUGuastallaJPNabholtzJM. Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (anastrozole and tamoxifen, alone or in combination) trial. Cancer2006;107:472480.

    • Search Google Scholar
    • Export Citation
  • 220.

    MouridsenHKeshaviahACoatesAS. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol2007;25:57155722.

    • Search Google Scholar
    • Export Citation
  • 221.

    RabaglioMSunZPriceKN. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol2009;20:14891498.

    • Search Google Scholar
    • Export Citation
  • 222.

    MouridsenHGiobbie-HurderAGoldhirschA. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med2009;361:766776.

    • Search Google Scholar
    • Export Citation
  • 223.

    BoccardoFRubagottiAPuntoniM. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol2005;23:51385147.

    • Search Google Scholar
    • Export Citation
  • 224.

    BoccardoFRubagottiAGuglielminiP. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol2006;17(Suppl 7):1014.

    • Search Google Scholar
    • Export Citation
  • 225.

    CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 226.

    JakeszRJonatWGnantM. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet2005;366:455462.

    • Search Google Scholar
    • Export Citation
  • 227.

    JonatWGnantMBoccardoF. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol2006;7:991996.

    • Search Google Scholar
    • Export Citation
  • 228.

    van de VeldeCJReaDSeynaeveC. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet2011;377:321331.

    • Search Google Scholar
    • Export Citation
  • 229.

    GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 230.

    GossPEIngleJNPaterJL. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol2008;26:19481955.

    • Search Google Scholar
    • Export Citation
  • 231.

    IngleJNTuDPaterJL. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol2008;19:877882.

    • Search Google Scholar
    • Export Citation
  • 232.

    PerezEAJosseRGPritchardKI. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol2006;24:36293635.

    • Search Google Scholar
    • Export Citation
  • 233.

    WhelanTJGossPEIngleJN. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol2005;23:69316940.

    • Search Google Scholar
    • Export Citation
  • 234.

    JakeszRGreilRGnantM. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst2007;99:18451853.

    • Search Google Scholar
    • Export Citation
  • 235.

    DowsettMCuzickJIngleJ. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol2010;28:509518.

    • Search Google Scholar
    • Export Citation
  • 236.

    SmithIEDowsettMYapYS. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol2006;24:24442447.

    • Search Google Scholar
    • Export Citation
  • 237.

    YuBDouglasNFerinMJ. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer2010;116:20992105.

    • Search Google Scholar
    • Export Citation
  • 238.

    DowsettMNielsenTOA’HernR. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst2011;103:16561664.

    • Search Google Scholar
    • Export Citation
  • 239.

    DowsettMSmithIEEbbsSR. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst2007;99:167170.

    • Search Google Scholar
    • Export Citation
  • 240.

    The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available at: http://www.cypalleles.ki.se/. Accessed March 7 2014.

  • 241.

    SchrothWGoetzMPHamannU. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA2009;302:14291436.

    • Search Google Scholar
    • Export Citation
  • 242.

    Leyland-JonesBReganMBouzykM. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial [abstract]. Cancer Res2010;70(24 Suppl):Abstract S1-8.

    • Search Google Scholar
    • Export Citation
  • 243.

    RaeJDrurySHayesD. Lack of correlation between gene variants in tamoxifen metabolizing enymes with primary endpoints in the ATAC trial [abstract]. Cancer Res2010;70(24 Suppl):Abstract S1-7.

    • Search Google Scholar
    • Export Citation
  • 244.

    HigginsMJStearnsV. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med2011;62:281293.

  • 245.

    VisvanathanKChlebowskiRTHurleyP. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol2009;27:32353258.

    • Search Google Scholar
    • Export Citation
  • 246.

    ErbanJKLauJ. On the toxicity of chemotherapy for breast cancer—the need for vigilance. J Natl Cancer Inst2006;98:10961097.

  • 247.

    HendersonIBerryDDemetriG. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol2003;21:976983.

    • Search Google Scholar
    • Export Citation
  • 248.

    MamounasEBryantJLemberskyB. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol2005;23:36863696.

    • Search Google Scholar
    • Export Citation
  • 249.

    CitronMLBerryDACirrincioneC. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 250.

    SparanoJAWangMMartinoS. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node positive or high risk node negative breast cancer [abstract]. Presented at the 28th Annual San Antonio Breast Cancer Symposium; December8-112005; San Antonio, Texas. Abstract 48.

    • Search Google Scholar
    • Export Citation
  • 251.

    SparanoJAWangMMartinoS. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup trial E1199 [abstract]. J Clin Oncol2007;25(Suppl 18):Abstract 516.

    • Search Google Scholar
    • Export Citation
  • 252.

    SparanoJWangMMartinoS. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med2008;358:16631671.

  • 253.

    JonesSHolmesFAO’ShaughnessyJ. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research trial 9735. J Clin Oncol2009;27:11771183.

    • Search Google Scholar
    • Export Citation
  • 254.

    BangSMHeoDSLeeKH. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer2000;89:25212526.

    • Search Google Scholar
    • Export Citation
  • 255.

    FisherBAndersonSTan-ChiuE. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol2001;19:931942.

    • Search Google Scholar
    • Export Citation
  • 256.

    FisherBBrownAMDimitrovNV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol1990;8:14831496.

    • Search Google Scholar
    • Export Citation
  • 257.

    FisherBAndersonSWickerhamDL. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol1997;15:18581869.

    • Search Google Scholar
    • Export Citation
  • 258.

    Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet1998;352:930942.

    • Search Google Scholar
    • Export Citation
  • 259.

    WoodWCBudmanDRKorzunAH. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med1994;330:12531259.

    • Search Google Scholar
    • Export Citation
  • 260.

    MenardSValagussaPPilottiS. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol2001;19:329335.

    • Search Google Scholar
    • Export Citation
  • 261.

    MussHBThorADBerryDA. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med1994;330:12601266.

    • Search Google Scholar
    • Export Citation
  • 262.

    WatanabeTKuranamiMInoueK. Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: results of N-SAS-BC02 trial [abstract]. J Clin Oncol2009;27(Suppl 15):Abstract 516.

    • Search Google Scholar
    • Export Citation
  • 263.

    LevineMPritchardKBramwellV. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol2005;23:51665170.

    • Search Google Scholar
    • Export Citation
  • 264.

    Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 Randomized Trial. J Clin Oncol2001;19:602611.

    • Search Google Scholar
    • Export Citation
  • 265.

    PiccartMJDi LeoABeauduinM. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol2001;19:31033110.

    • Search Google Scholar
    • Export Citation
  • 266.

    EllisPBarrett-LeePJohnsonL. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet2009;373:16811692.

    • Search Google Scholar
    • Export Citation
  • 267.

    MartinMRodriguez-LescureARuizA. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst2008;100:805814.

    • Search Google Scholar
    • Export Citation
  • 268.

    MartinMPienkowskiTMackeyJ. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med2005;352:23022313.

  • 269.

    SwainSMJeongJHGeyerCE. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer [abstract]. Cancer Res2009;69(Suppl 1):Abstract 75.

    • Search Google Scholar
    • Export Citation
  • 270.

    BursteinHJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med2005;353:16521654.

  • 271.

    JoensuuHBonoPKatajaV. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol2009;27:56855692.

    • Search Google Scholar
    • Export Citation
  • 272.

    PerezEARomondEHSumanVJ. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol2011;29:33663373.

    • Search Google Scholar
    • Export Citation
  • 273.

    GianniLDafniUGelberRD. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol2011;12:236244.

    • Search Google Scholar
    • Export Citation
  • 274.

    PerezEASumanVJDavidsonNE. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol2008;26:12311238.

    • Search Google Scholar
    • Export Citation
  • 275.

    Tan-ChiuEYothersGRomondE. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol2005;23:78117819.

    • Search Google Scholar
    • Export Citation
  • 276.

    GeyerCEJrBryantJLRomondEH. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H) [abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 581.

    • Search Google Scholar
    • Export Citation
  • 277.

    TelliMLHuntSACarlsonRWGuardinoAE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol2007;25:35253533.

    • Search Google Scholar
    • Export Citation
  • 278.

    SmithIProcterMGelberRD. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet2007;369:2936.

    • Search Google Scholar
    • Export Citation
  • 279.

    SpielmannMRochéHDelozierT. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol2009;27:61296134.

    • Search Google Scholar
    • Export Citation
  • 280.

    ChiaSNorrisBSpeersC. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol2008;26:56975704.

    • Search Google Scholar
    • Export Citation
  • 281.

    Gonzalez-AnguloAMLittonJKBroglioKR. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol2009;27:57005706.

    • Search Google Scholar
    • Export Citation
  • 282.

    O’SullivanCHolmesESpielmannM. The prognosis of small HER2+ breast cancers: a meta-analysis of the randomized trastuzumab trials [abstract]. Presented at the 2013 San Antonio Breast Cancer Symposium; December10-142013; San Antonio, Texas. Abstract S6-03

    • Search Google Scholar
    • Export Citation
  • 283.

    ZhouQYinWDuYLuJ. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures. PLoS One2014;9:e83646.

    • Search Google Scholar
    • Export Citation
  • 284.

    TolaneySBarryWDangC. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) [abstract]. Presented at the 2013 San Antonio Breast Cancer Symposium; December10-142013; San Antonio, Texas. Abstract S1-04.

    • Search Google Scholar
    • Export Citation
  • 285.

    NorrisBChiaSCheangM. Poor 10 yr breast cancer specific survival and relapse free survival for HER2 positive T1N0 tumors [abstract]. Presented at the 29th San Antonio Breast Cancer Symposium; December14-172006; San Antonio, Texas. Abstract 2031.

    • Search Google Scholar
    • Export Citation
  • 286.

    CuriglianoGVialeGBagnardiV. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol2009;27:56935699.

    • Search Google Scholar
    • Export Citation
  • 287.

    PerezEARomondEHSumanVJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol2007;25(Suppl 18):Abstract 512.

    • Search Google Scholar
    • Export Citation
  • 288.

    UntchMGelberRDJackischC. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol2008;19:10901096.

    • Search Google Scholar
    • Export Citation
  • 289.

    vonMGBaselgaJBradburyI. Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4-11/BO25126/TOC4939g) [abstract]. Cancer Res2011;71(Suppl 24):Abstract OT1-02-04.

    • Search Google Scholar
    • Export Citation
  • 290.

    A randomized multicenter double-blind placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breastClinicalTrials.govidentifier: NCT01358877.

    • Search Google Scholar
    • Export Citation
  • 291.

    Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA1994;271:15871592.

    • Search Google Scholar
    • Export Citation
  • 292.

    Rosselli Del TurcoMPalliDCariddiA. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA1994;271:15931597.

    • Search Google Scholar
    • Export Citation
  • 293.

    SmithTJDavidsonNESchapiraDV. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol1999;17:10801082.

    • Search Google Scholar